Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Pyxis Oncology, Inc.NASDAQ: PYXS
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 52.7% from a year ago
Total assets stood at $64.3M at the end of Q1 FY2026, down 52.7% from a year earlier and down 29.7% from the prior quarter. Over 3 fiscal years it compounded at -24.3% a year.
Context
- Total assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -52.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 91.52M USD
- Year-over-year change
- -41.8%
- 4-year CAGR
- -24.4%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 91.52M | -41.8% |
| FY2024 | 2024-12-31 | 157.18M | -9.5% |
| FY2023 | 2023-12-31 | 173.73M | -17.8% |
| FY2022 | 2022-12-31 | 211.38M | -24.5% |
| FY2021 | 2021-12-31 | 280.02M | — |
Total Assets vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's Mar 2026 total assets of $64.3M is the lowest of the 10 companies compared; the peer median is $222.17M.
- Its year-over-year change of -52.7% is the lowest of 10, against a peer median of -14.1%.
- Over three fiscal years its annual growth of -24.3% compares with a peer median of -17.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $214.81B | +423744.3% | +23.8% | |
| Mar 2026 | $314.7M | -2.6% | -9.6% | |
| Mar 2026 | $267.08M | -39.3% | -22.1% | |
ZURAZura Bio Limited | Mar 2026 | $228.64M | +32.5% | +178.7% |
| Mar 2026 | $222.17M | -14.1% | -21.2% | |
| Mar 2026 | $219.33M | -37.9% | +16.5% | |
| Mar 2026 | $149M | -45.6% | -22.3% | |
| Mar 2026 | $135.07M | -6.2% | -19.2% | |
| Mar 2026 | $110.56M | -32.0% | -17.1% | |
| Mar 2026 | $64.3M | -52.7% | -24.3% | |
| Peer median (excluding PYXS) | $222.17M | -14.1% | -17.1% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 274.74M | 179.29M | 9.66M | 19.47M | 15.42M |
| Short-term Investments | 0 | 0 | 109.63M | 107.46M | 51.44M |
| Net Receivables | 0 | 598K | 21K | 0 | 700K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.56M | 5.41M | 4.27M | 4.75M | 4.55M |
| Total Current Assets | 278.67M | 186.61M | 124.6M | 132.44M | 72.11M |
| Property, Plant & Equipment (Net) | 1.24M | 24.77M | 24.81M | 22.14M | 19.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 24.31M | 2.6M | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 109K | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 1.35M | 24.77M | 49.12M | 24.74M | 19.42M |
| Total Assets | 280.02M | 211.38M | 173.73M | 157.18M | 91.52M |
| Account Payables | 11.95M | 7.1M | 3.9M | 4.86M | 10.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 7.66M | 0 | 0 |
| Other Current Liabilities | 3.23M | 5.33M | 5.58M | 4.63M | 3.75M |
| Total Current Liabilities | 18.71M | 31.63M | 25.76M | 17.68M | 21.13M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 2.16M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 18.92M | 22.26M | 18.75M | 16.98M |
| Total Liabilities | 18.71M | 50.56M | 48.02M | 36.43M | 38.11M |
| Common Stock | 32K | 34K | 45K | 60K | 63K |
| Retained Earnings | (91.72M) | (212.44M) | (286.23M) | (363.56M) | (443.18M) |
| Accumulated OCI | 0 | 0 | 63K | 170K | 53K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 261.31M | 160.82M | 125.7M | 120.75M | 53.41M |
| Total Debt | 165K | 18.92M | 21.33M | 20.2M | 18.67M |
| Net Debt | (274.57M) | (160.37M) | 11.67M | 727K | 3.25M |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.